Aria CV
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
$7.8m | Series A | ||
N/A | $1.9m | Early VC | |
* | $31.0m | Series B | |
* | N/A | $13.0m Valuation: $155m | Late VC |
Total Funding | AUD83.0m |
Recent News about Aria CV
EditAria CV is a medical device company focused on developing a novel implantable device designed to treat pulmonary hypertension (PH). The company's core product is an elegant device that operates without batteries, pumps, or electronics, relying entirely on the motion of the heart. This device consists of four simple components: a reservoir, a balloon, a narrow conduit allowing gas movement, and a nitinol anchor that holds the balloon in place. Aria CV primarily serves patients suffering from pulmonary hypertension, a condition characterized by high blood pressure in the lungs' arteries, which can lead to heart failure if untreated. The company operates in the medical device market, targeting healthcare providers and institutions involved in treating PH. Aria CV's business model revolves around clinical trials and investigational use, aiming to gain regulatory approval for widespread adoption. Revenue generation is expected through the commercialization of the device post-approval, focusing on partnerships with healthcare providers and direct sales to medical institutions.
Keywords: pulmonary hypertension, implantable device, medical innovation, heart-driven, clinical trials, healthcare providers, regulatory approval, nitinol anchor, gas conduit, investigational use.